171 related articles for article (PubMed ID: 8222482)
41. Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 2000; 16():280-4. PubMed ID: 11045311
[TBL] [Abstract][Full Text] [Related]
42. [Pharmacokinetics of vancomycin in chronic renal failure patients in continuous ambulatory peritoneal dialysis (CAPD) after intra-abdominal administration].
Mounier M; Benevent D; Denis F
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):542-4. PubMed ID: 3911152
[TBL] [Abstract][Full Text] [Related]
43. Continuous ambulatory peritoneal dialysis- a new dimension in the treatment of end-stage renal disease.
Shohat J; Boner G; Rosenfeld J; Waller A; Iaina A; Eliahou HE
Isr J Med Sci; 1982 Oct; 18(10):1014-8. PubMed ID: 7174268
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis using 99mTc-solid meal.
Hubalewska A; Stompór T; Płaczkiewicz E; Staszczak A; Huszno B; Sułowicz W; Szybiński Z
Nucl Med Rev Cent East Eur; 2004; 7(1):27-30. PubMed ID: 15318307
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of single-dose rosiglitazone in chronic ambulatory peritoneal dialysis patients.
Aramwit P; Supasyndh O; Sriboonruang T
J Clin Pharm Ther; 2008 Dec; 33(6):685-90. PubMed ID: 19138247
[TBL] [Abstract][Full Text] [Related]
46. Insulin resistance in dialysis versus non dialysis end stage renal disease patients without diabetes.
Satirapoj B; Supasyndh O; Phantana-Angkul P; Ruangkanchanasetr P; Nata N; Chaiprasert A; Kanjanakul I; Choovichian P
J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S87-93. PubMed ID: 22043573
[TBL] [Abstract][Full Text] [Related]
47. Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis.
O'Brien MA; Mason NA
Clin Pharm; 1992 Mar; 11(3):246-54. PubMed ID: 1611814
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis.
Browning MJ; Holt HA; White LO; Chapman ST; Banks RA; Reeves DS; Yates RA
J Antimicrob Chemother; 1986 Jul; 18(1):103-6. PubMed ID: 3463556
[TBL] [Abstract][Full Text] [Related]
49. Serum levels and peritoneal loss of prolactin in CAPD patients.
Kagan A; Gertler A; Ulman M; Bar-Khayim Y
Adv Perit Dial; 1991; 7():247-52. PubMed ID: 1680437
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis.
Grech-Bélanger O; Langlois S; LeBoeuf E
J Clin Pharmacol; 1988 May; 28(5):477-80. PubMed ID: 3392246
[TBL] [Abstract][Full Text] [Related]
51. Myoglobin elimination in end stage kidney disease patients on renal replacement treatment.
Stefanović V; Bogićević M; Mitić M
Int J Artif Organs; 1993 Sep; 16(9):659-61. PubMed ID: 8294158
[TBL] [Abstract][Full Text] [Related]
52. Plasma free amino acids and their metabolites in Taiwanese patients on hemodialysis and continuous ambulatory peritoneal dialysis.
Chuang CK; Lin SP; Chen HH; Chen YC; Wang TJ; Shieh WH; Wu CJ
Clin Chim Acta; 2006 Feb; 364(1-2):209-16. PubMed ID: 16087168
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.
Barbhaiya RH; Knupp CA; Pfeffer M; Zaccardelli D; Dukes GM; Mattern W; Pittman KA; Hak LJ
Antimicrob Agents Chemother; 1992 Jul; 36(7):1387-91. PubMed ID: 1510432
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of oral cephradine in continuous ambulatory peritoneal dialysis patients.
Johnson CA; Welling PG; Zimmerman SW
Nephron; 1984; 38(1):57-61. PubMed ID: 6472532
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis.
Ahern MJ; Finkelstein FO; Andriole VT
Antimicrob Agents Chemother; 1976 Sep; 10(3):457-61. PubMed ID: 984787
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis.
Joffe P; Thomsen HS; Meusel M
Acad Radiol; 1998 Jul; 5(7):491-502. PubMed ID: 9653466
[TBL] [Abstract][Full Text] [Related]
57. Dementia and depression in end stage renal disease: comparison between hemodialysis and continuous ambulatory peritoneal dialysis.
Sithinamsuwan P; Niyasom S; Nidhinandana S; Supasyndh O
J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S141-7. PubMed ID: 16858952
[TBL] [Abstract][Full Text] [Related]
58. Behavior of beta 2-microglobulin in patients with chronic renal failure undergoing hemodialysis, hemodiafiltration and continuous ambulatory peritoneal dialysis (CAPD).
Blumberg A; Bürgi W
Clin Nephrol; 1987 May; 27(5):245-9. PubMed ID: 3297439
[TBL] [Abstract][Full Text] [Related]
59. Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis.
Keller E; Jansen A; Pelz K; Hoppe-Seyler G; Schollmeyer P
Clin Pharmacol Ther; 1984 Feb; 35(2):208-13. PubMed ID: 6692648
[TBL] [Abstract][Full Text] [Related]
60. Protein C, protein S, and antithrombin III levels in patients on continuous ambulatory peritoneal dialysis and hemodialysis.
Lai KN; Yin JA; Yuen PM; Li PK
Nephron; 1990; 56(3):271-6. PubMed ID: 2150218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
